E-health Psychological Intervention in Pregnant Women Exposed to Intimate Partner Violence (eIPV) (eIPV)

January 9, 2023 updated by: Antonella Ludmila Zapata Calvente, Universidad de Granada

E-health Psychological Intervention in Pregnant Women Exposed to Intimate Partner Violence (eIPV): a Pilot Randomised Controlled Trial

The investigators will assess the need and feasibility of randomising a sufficiently large number of women exposed to IPV during pregnancy in a full-scale future randomised trial. To achieve this, the investigators will:

  1. estimate rates of consent to randomization, and the rates of adherence and dropout following randomization (for the use in sample size estimation)
  2. determine recruitment duration
  3. examine the women's perception about the benefit of the intervention
  4. determine the reasons for acceptability, non-adherence, and obstacles to recruitment, randomisation and consent through qualitative interviews

Study Overview

Detailed Description

Introduction. Intimate partner violence (IPV) during pregnancy, a condition as common as obstetrics conditions like gestational diabetes, is associated with maternal and neonatal complications. Systematic detection of IPV is not well established in antenatal screening probably because the effectiveness of protective interventions has not been evaluated. Among mothers exposed to IPV, e-health interventions during pregnancy may be beneficial. Prior to performing a full-scale effectiveness trial for such an intervention, a pilot study is required to assess the need and feasibility of randomising a sufficiently large number of women at exposed to IPV during pregnancy.

Methods. The eIPV trial is a randomised pilot study nested within a cohort of consenting mothers at <12 weeks' gestation who screen positive for IPV in the first antenatal visit and accept an e-health package (psychological counselling by videoconference) in Spain and Denmark. Twenty eligible mothers from the above cohort will be randomised to either intervention or control. The intervention group will receive the e-health package as part of the cohort. The control group will be invited to accept a delay in the intervention (e-health package eight weeks later). After consenting to delay, the control group will provide comparative data without losing the opportunity of obtaining the intervention. The investigators will determine estimates of rates of informed consent to randomization, and the rates of adherence and dropout following randomization. Qualitative interviews will be conducted to examine the women's perception about the benefit of the intervention, reasons for acceptability and non-adherence, and obstacles to recruitment, randomisation and consent. The results will inform the feasibility and variance of key clinical outcome measures for estimation of sample size of the full-scale effectiveness trial.

Comment. The pilot study nested within the cohort study will allow us to obtain information about the rates of IPV in pregnancy, the acceptability of an e-health intervention and the availability of participants for randomisation into a large effectiveness trial.

Study Type

Interventional

Enrollment (Actual)

24

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Odense, Denmark
        • Odense University Hospital
      • Granada, Spain
        • University of Granada

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

16 years and older (Child, Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

Female

Description

Inclusion Criteria:

• Pregnant women at <12 weeks gestation, who screen positive in IPV at the first antenatal visit and accept the e-health package.

Exclusion Criteria:

  • Women who cannot be informed about the study without their partners or other family members knowing
  • Women mentally or physically incapacity to participate in the study
  • Women below 16 years in Spain or below 18 years in Denmark
  • Inability to understand Danish/Spanish
  • Lack of internet and electronic device
  • Women with extreme severity of IPV. Women selected to participate in the trial in this situation will receive a danger assessment before randomisation and if the severity of IPV is confirmed, they will be routinely treated and supported according to the standard protocol in each country. Women who have same-sex partners will be screened, but their data will not be used for the purpose of this study.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Supportive Care
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Intervention group
Behavioral e-health psychological counselling

Intervention group: Women positive for IPV who accept the e-Health intervention and who have been randomly allocated in the intervention group will receive the e-health package as the rest of the cohort, as well as the baseline and outcome measurements. The e-health package will include six video counselling sessions by trained providers and the access to a mobile application for designing security plans, an adapted version of the mobile application "My Plan". The content of the six individually tailored sessions will be based on the Dutton's Empowerment Model and the Psychosocial Readiness Model.

Control group: women positive in IPV who accept the e-Health intervention package will be asked for a second consent to receive a delayed intervention (8 weeks later) and to complete as the baseline and outcome measurements. Women can request to leave the control group at any time and to receive the intervention immediately (in which case they data will be part of the cohort study).

Other: Control group
Usual care (delayed behavioral e-health psychological counselling)

Intervention group: Women positive for IPV who accept the e-Health intervention and who have been randomly allocated in the intervention group will receive the e-health package as the rest of the cohort, as well as the baseline and outcome measurements. The e-health package will include six video counselling sessions by trained providers and the access to a mobile application for designing security plans, an adapted version of the mobile application "My Plan". The content of the six individually tailored sessions will be based on the Dutton's Empowerment Model and the Psychosocial Readiness Model.

Control group: women positive in IPV who accept the e-Health intervention package will be asked for a second consent to receive a delayed intervention (8 weeks later) and to complete as the baseline and outcome measurements. Women can request to leave the control group at any time and to receive the intervention immediately (in which case they data will be part of the cohort study).

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Consent rate for a future full-scale RCT trial
Time Frame: Three to nine months
Rate of women who were positive in IPV, consent to receive e-health package and consent to randomization in the control group.
Three to nine months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Positivity rate of the cohort study (useful for planning the future full-scale randomised control trial):
Time Frame: Three to nine months
Rate of women who were positive in IPV and consent to receive e-health package
Three to nine months
Completion rate in the intervention group a future full-scale RCT trial
Time Frame: Three to nine months
Rate of women who were recruited to intervention group, and for whom complete outcomes were obtained.
Three to nine months
Completion rate in the control group a future full-scale RCT trial
Time Frame: Three to nine months
Rate of women who were recruited to control group, and for whom complete outcomes were obtained.
Three to nine months
Recruitment duration for a future full-scale RCT trial
Time Frame: Three to nine months
Recruitment duration (in days) to get the pilot sample (5 women for the intervention group and 5 women for the control group, in each country)
Three to nine months
Benefit of the intervention a future full-scale RCT trial
Time Frame: Three to nine months
Perception of the intervention by women participating in the pilot through the information obtained in qualitative interviews.
Three to nine months
Perception about the delay of the intervention of the control group for a future full-scale RCT trial
Time Frame: Three to nine months
Perception about the duration of delay of the intervention of women in the control group (provided in the qualitative interviews).
Three to nine months
Reasons for acceptability, non-adherence, and obstacles for a future full-scale RCT trial
Time Frame: Three to nine months
Reasons for acceptability, non-adherence, and obstacles to recruitment, randomization, consent and follow-up (provided in the qualitative interviews).
Three to nine months
Follow up rate for a future full-scale RCT trial
Time Frame: Three to nine months
Rate of failure to obtain data in the follow-up.
Three to nine months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Study Director: Khalid S. Khan, Universidad de Granada

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

October 7, 2021

Primary Completion (Actual)

November 14, 2022

Study Completion (Actual)

November 14, 2022

Study Registration Dates

First Submitted

July 4, 2021

First Submitted That Met QC Criteria

July 15, 2021

First Posted (Actual)

July 27, 2021

Study Record Updates

Last Update Posted (Estimate)

January 10, 2023

Last Update Submitted That Met QC Criteria

January 9, 2023

Last Verified

January 1, 2023

More Information

Terms related to this study

Other Study ID Numbers

  • eIPV
  • 202167133116 (Other Identifier: Andalusian Research Ethics Committee)
  • 20212000-80 (Other Identifier: Regional Committees Health Research Ethics Southern Denmark)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

Yes

IPD Plan Description

We will collaborate in an approved, registered Individual Participant Data metaanalysis

IPD Sharing Time Frame

Starting 6 months after publication

IPD Sharing Access Criteria

On reasonable request, protocol, data collection forms and published results are available from investigators. Sharing would need to be comply with data protection laws.

IPD Sharing Supporting Information Type

  • Study Protocol
  • Informed Consent Form (ICF)
  • Clinical Study Report (CSR)

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Pregnancy Related

Clinical Trials on e-health psychological counselling

3
Subscribe